Recent data demonstrated that mutations of these two genes have opposite consequences on PARPi sensitivity in acute myeloid leukaemia (AML) cells expressing oncogenic tyrosine kinases (e.g., mutated FLT3 or JAK2), which are characterised by high endogenous levels of DNA DSB. The gene discussed is FLT3; the disease is acute myeloid leukemia.